ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ITRM Iterum Therapeutics PLC

1.55
-0.06 (-3.73%)
11 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Iterum Therapeutics PLC NASDAQ:ITRM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.06 -3.73% 1.55 1.17 2.95 1.60 1.50 1.59 110,155 05:00:12

Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat

15/03/2024 12:00pm

GlobeNewswire Inc.


Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart


From Mar 2024 to May 2024

Click Here for more Iterum Therapeutics Charts.

Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, announced today that the company will participate in a virtual H.C. Wainwright @Home Fireside Chat on March 21, 2024. Corey Fishman, Iterum’s Chief Executive Officer, Sailaja Puttagunta, M.D., Iterum’s Chief Medical Officer, and Judy Matthews, Iterum’s Chief Financial Officer, will discuss Iterum’s lead program, oral sulopenem, for the treatment of adult women with uncomplicated urinary tract infections (uUTI).

H.C. Wainwright @Home with Iterum Therapeutics plc (ITRM)

Date: Thursday, March 21, 2024

Time: 10:00 A.M.- 11:00 A.M. Eastern Time

Format: Fireside Chat

Host: Ed Arce, Managing Director and Senior Healthcare Analyst

Registration: Click here

The webcast presentation replay will be available for viewing on the Events & Presentations section of Iterum’s website following the presentation.

About Iterum Therapeutics plc

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is currently advancing its first compound – sulopenem – a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com.

Investor Contact:Judy Matthews Chief Financial Officer312-778-6073IR@iterumtx.com    

1 Year Iterum Therapeutics Chart

1 Year Iterum Therapeutics Chart

1 Month Iterum Therapeutics Chart

1 Month Iterum Therapeutics Chart

Your Recent History

Delayed Upgrade Clock